Market Overview:
The global critical care therapeutics market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to factors such as rising incidence of chronic diseases, increasing demand for prothrombin complex concentrates (PCCs), and growing geriatric population. However, the high cost of treatment and lack of awareness about critical care therapies are some factors that may restrain the growth of this market during the forecast period. On the basis of type, albumin accounted for the largest share in 2017 and is projected to grow at a CAGR of 5.4% from 2018 to 2030. This can be attributed to its wide range of applications in various medical conditions such as sepsis, burns, trauma, and hypovolemic shock.
Product Definition:
Critical care therapeutics is the term used to describe drugs and treatments that are administered to patients who are critically ill. The purpose of critical care therapeutics is to improve the patient's condition and help them recover. Critical care therapies can include medication, mechanical ventilation, dialysis, and other treatments.
Albumin:
Albumin is a protein that is found in the plasma and urine. It has a molecular weight of 56-60 kilodaltons. The normal range for human serum albumin level is 3.5 - 7.8 g/L and for human plasma albumin level it ranges from 4 – 11 g/L.
Prothrombin Complex Concentrates:
Prothrombin complex concentrates are a group of medicines used to treat complicated bleeding. The active ingredient in this product helps the blood coagulation process by increasing the prothrombin activity. This is an important factor as too much blood loss can cause low blood pressure, which may lead to death of the patient if not treated with appropriate fluids and drugs.
Application Insights:
Acute coronary syndrome held the largest share of 24.1% in 2017 owing to a high prevalence of risk factors such as diabetes, smoking and obesity. According to the CDC, around 647,000 deaths occur due to cardiovascular diseases in U.S., which is also the leading cause of death in this country. The segment is expected to witness lucrative growth during forecast period owing to increasing incidence rates for acute coronary syndrome across developed countries such as Germany and France.
The other application segment comprises of sepsis and respiratory failure cases that require ICU admission for treatment where critical care therapeutics are used at its highest dosage level or until it becomes unnecessary.
Regional Analysis:
North America dominated the global market in 2017. The presence of well-established healthcare facilities, favorable reimbursement policies, and increasing awareness among individuals about early diagnosis are some of the major factors responsible for this dominance. Moreover, rising preference for outpatient settings over inpatient ones is also expected to drive growth during the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing regions during the same period owing to improving healthcare infrastructure and growing patient awareness levels regarding critical care therapeutics products. Furthermore, economic development coupled with government initiatives such as “Hospital Improvement Program†(HIP) aimed at improving hospital management practices is further expected to boost regional growth over next eight years.
Growth Factors:
- Increasing incidence of critical care diseases: The global critical care therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of critical care diseases such as sepsis, pneumonia, and meningitis.
- Growing demand for novel drugs: The demand for novel drugs is expected to drive the growth of the global critical care therapeutics market during the forecast period. Novel drugs are those that offer better efficacy and safety as compared to existing therapies and are thus preferred by physicians and patients alike.
- Rising geriatric population: The geriatric population is susceptible to various critical care diseases, which is expected to drive the growth of the global Critical Care Therapeutics market during the forecast period. According to a study by United Nations Department of Economic Affairs (UNDESA), it is estimated that there will be more than 1 billion people aged 60 years or above by 2050, accounting for nearly 22% of world’s population. This growing geriatric population will create a high demand for effective treatments for various critical care diseases in future years..
Scope Of The Report
Report Attributes
Report Details
Report Title
Critical Care Therapeutics Market Research Report
By Type
Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates, Factor XIII Concentrates, Fibrinogen Concentrates
By Application
Pulmonary Embolism (PE), Acute Coronary Syndrome, Atrial Fibrillation, Other
By Companies
CSL Behring, Grifols, Kedrion Biopharma, Octapharma, Takeda, Bayer HealthCare, Merck, Mitsubishi Tanabe Pharma, REVO Biologics, Rockwell Medical, Thermo Fisher Scientific, Shanghai RAAS, China Biologic Products, Cosmo Pharmaceuticals, King Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
224
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Critical Care Therapeutics Market Report Segments:
The global Critical Care Therapeutics market is segmented on the basis of:
Types
Albumin, Prothrombin Complex Concentrates, Antithrombin Concentrates, Factor XIII Concentrates, Fibrinogen Concentrates
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Pulmonary Embolism (PE), Acute Coronary Syndrome, Atrial Fibrillation, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- CSL Behring
- Grifols
- Kedrion Biopharma
- Octapharma
- Takeda
- Bayer HealthCare
- Merck
- Mitsubishi Tanabe Pharma
- REVO Biologics
- Rockwell Medical
- Thermo Fisher Scientific
- Shanghai RAAS
- China Biologic Products
- Cosmo Pharmaceuticals
- King Pharmaceuticals
Highlights of The Critical Care Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Albumin
- Prothrombin Complex Concentrates
- Antithrombin Concentrates
- Factor XIII Concentrates
- Fibrinogen Concentrates
- By Application:
- Pulmonary Embolism (PE)
- Acute Coronary Syndrome
- Atrial Fibrillation
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Critical Care Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Critical Care Therapeutics is a global biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious medical conditions. The company's product candidates include CAR-T cell therapies for cancer, rare diseases and other life-threatening conditions.
Some of the key players operating in the critical care therapeutics market are CSL Behring, Grifols, Kedrion Biopharma, Octapharma, Takeda, Bayer HealthCare, Merck, Mitsubishi Tanabe Pharma, REVO Biologics, Rockwell Medical, Thermo Fisher Scientific, Shanghai RAAS, China Biologic Products, Cosmo Pharmaceuticals, King Pharmaceuticals.
The critical care therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Critical Care Therapeutics Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Critical Care Therapeutics Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Critical Care Therapeutics Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Critical Care Therapeutics Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Critical Care Therapeutics Market Size & Forecast, 2018-2028
4.5.1 Critical Care Therapeutics Market Size and Y-o-Y Growth
4.5.2 Critical Care Therapeutics Market Absolute $ Opportunity
Chapter 5 Global Critical Care Therapeutics Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Critical Care Therapeutics Market Size Forecast by Type
5.2.1 Albumin
5.2.2 Prothrombin Complex Concentrates
5.2.3 Antithrombin Concentrates
5.2.4 Factor XIII Concentrates
5.2.5 Fibrinogen Concentrates
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Critical Care Therapeutics Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Critical Care Therapeutics Market Size Forecast by Applications
6.2.1 Pulmonary Embolism (PE)
6.2.2 Acute Coronary Syndrome
6.2.3 Atrial Fibrillation
6.2.4 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Critical Care Therapeutics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Critical Care Therapeutics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Critical Care Therapeutics Analysis and Forecast
9.1 Introduction
9.2 North America Critical Care Therapeutics Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Critical Care Therapeutics Market Size Forecast by Type
9.6.1 Albumin
9.6.2 Prothrombin Complex Concentrates
9.6.3 Antithrombin Concentrates
9.6.4 Factor XIII Concentrates
9.6.5 Fibrinogen Concentrates
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Critical Care Therapeutics Market Size Forecast by Applications
9.10.1 Pulmonary Embolism (PE)
9.10.2 Acute Coronary Syndrome
9.10.3 Atrial Fibrillation
9.10.4 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Critical Care Therapeutics Analysis and Forecast
10.1 Introduction
10.2 Europe Critical Care Therapeutics Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Critical Care Therapeutics Market Size Forecast by Type
10.6.1 Albumin
10.6.2 Prothrombin Complex Concentrates
10.6.3 Antithrombin Concentrates
10.6.4 Factor XIII Concentrates
10.6.5 Fibrinogen Concentrates
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Critical Care Therapeutics Market Size Forecast by Applications
10.10.1 Pulmonary Embolism (PE)
10.10.2 Acute Coronary Syndrome
10.10.3 Atrial Fibrillation
10.10.4 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Critical Care Therapeutics Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Critical Care Therapeutics Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Critical Care Therapeutics Market Size Forecast by Type
11.6.1 Albumin
11.6.2 Prothrombin Complex Concentrates
11.6.3 Antithrombin Concentrates
11.6.4 Factor XIII Concentrates
11.6.5 Fibrinogen Concentrates
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Critical Care Therapeutics Market Size Forecast by Applications
11.10.1 Pulmonary Embolism (PE)
11.10.2 Acute Coronary Syndrome
11.10.3 Atrial Fibrillation
11.10.4 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Critical Care Therapeutics Analysis and Forecast
12.1 Introduction
12.2 Latin America Critical Care Therapeutics Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Critical Care Therapeutics Market Size Forecast by Type
12.6.1 Albumin
12.6.2 Prothrombin Complex Concentrates
12.6.3 Antithrombin Concentrates
12.6.4 Factor XIII Concentrates
12.6.5 Fibrinogen Concentrates
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Critical Care Therapeutics Market Size Forecast by Applications
12.10.1 Pulmonary Embolism (PE)
12.10.2 Acute Coronary Syndrome
12.10.3 Atrial Fibrillation
12.10.4 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Critical Care Therapeutics Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Critical Care Therapeutics Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Critical Care Therapeutics Market Size Forecast by Type
13.6.1 Albumin
13.6.2 Prothrombin Complex Concentrates
13.6.3 Antithrombin Concentrates
13.6.4 Factor XIII Concentrates
13.6.5 Fibrinogen Concentrates
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Critical Care Therapeutics Market Size Forecast by Applications
13.10.1 Pulmonary Embolism (PE)
13.10.2 Acute Coronary Syndrome
13.10.3 Atrial Fibrillation
13.10.4 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Critical Care Therapeutics Market: Competitive Dashboard
14.2 Global Critical Care Therapeutics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 CSL Behring
14.3.2 Grifols
14.3.3 Kedrion Biopharma
14.3.4 Octapharma
14.3.5 Takeda
14.3.6 Bayer HealthCare
14.3.7 Merck
14.3.8 Mitsubishi Tanabe Pharma
14.3.9 REVO Biologics
14.3.10 Rockwell Medical
14.3.11 Thermo Fisher Scientific
14.3.12 Shanghai RAAS
14.3.13 China Biologic Products
14.3.14 Cosmo Pharmaceuticals
14.3.15 King Pharmaceuticals
